Qualifying Therapeutic Discovery Project Grants for the State of Louisiana
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Autoimmune Technologies, LLC | Flufirvitide-3: A Broad-Spectrum Entry-inhibiting Seasonal and Pandemic Influenza Drug | $ 216,310.35 | $ 28,168.90 |
| DEKK-Tec, Inc. | The Clinical Development of 4-Demethylcholesterloxycarbonylpenclomedine.The Clinical Development of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) for the Treatment of Cancers Involving the Central Nervous System | $ 126,990.50 | $ 117,488.74 |
| Embera Neuro Therapeutics, Inc. | EMB-001: A novel pharmaceutical product for the treatment of addictive disorders | $ 244,479.24 | |
| Esperance Pharmaceuticals, Inc | The Development of a Cationic Lytic Peptide (CLYPTM) Technology Platform | $ 244,479.24 | |
| Meta Logos Inc | Trace-level biosensing for early detection, and treatment, of cancer and other diseases. | $ 137,500.00 | $ 106,979.24 |
| NuPotential,Inc. | A new Approach to Regenerative Medicine Development | $ 244,479.25 | |
| TCA Cellular Therapy LLC | TCA Cellular Therapies for treatment of cardiovascular and neurological disease. | $ 168,075.93 | $ 76,403.32 |
| TRANSGENRX, INC. | Engineered glycosylated interferons for the treatment of viral diseases, Melanoma and MS | $ 244,479.25 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
